Literature DB >> 12772437

Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study.

G Roselli della Rovere1, A Lapolla, G Sartore, C Rossetti, S Zambon, N Minicuci, G Crepaldi, D Fedele, E Manzato.   

Abstract

BACKGROUND AND AIM: To evaluate the role of lipoprotein abnormalities as risk factors for macroangiopathy in Type 2 diabetes. METHODS AND
RESULTS: This prospective nine-year follow-up study involved 113 Type 2 diabetic patients (50 men and 63 women, mean age 66.9 +/- 9.9 years), 37 of whom had clinical signs of coronary heart disease (CHD) and cerebrovascular disease (CVD) at baseline. During the follow-up, 32 patients died: 17 of CHD, five of CVD, and 10 of non-vascular causes. The patients who died because of vascular disease were more frequently smokers, and had baseline symptoms of vascular disease; they were also significantly different from the other patients insofar as they were older, and had higher fasting plasma glucose levels, lower fasting C-peptide levels, and lower apoprotein (apo) AII, apo CII, apo CIII and apo E levels. Univariate analysis showed that baseline symptoms of vascular disease, current smoking, age, high fasting plasma glucose levels, low fasting C-peptide levels, and low apo AII, apo CII, apo CIII and apo E levels [but not cholesterol, triglyceride, high-density lipoprotein (HDL)-cholesterol or qualitative low-density lipoprotein or HDL abnormalities] were associated with cardiovascular mortality. Multivariate analysis showed that only age, smoking, glycated hemoglobin (HbA1c) and fasting C-peptide levels were significant independent determinants of macrovascular death.
CONCLUSIONS: In Type 2 normolipidemic diabetic patients, only age, smoking, HbA1c and fasting C-peptide levels are independent vascular risk factors. The differences in apo concentrations between patients with and without vascular disease may reflect qualitative abnormalities in plasma lipoproteins related to vascular disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12772437     DOI: 10.1016/s0939-4753(03)80167-9

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  10 in total

1.  Speciated human high-density lipoprotein protein proximity profiles.

Authors:  Kekulawalage Gauthamadasa; Corina Rosales; Henry J Pownall; Stephen Macha; W Gray Jerome; Rong Huang; R A Gangani D Silva
Journal:  Biochemistry       Date:  2010-11-23       Impact factor: 3.162

2.  The interaction between ApoA2 -265T>C polymorphism and dietary fatty acids intake on oxidative stress in patients with type 2 diabetes mellitus.

Authors:  Elham Zamani; Haleh Sadrzadeh-Yeganeh; Gity Sotoudeh; Laleh Keramat; Mohammadreza Eshraghian; Masoumeh Rafiee; Fariba Koohdani
Journal:  Eur J Nutr       Date:  2016-06-06       Impact factor: 5.614

3.  Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes.

Authors:  Helen C Looker; Marco Colombo; Felix Agakov; Tanja Zeller; Leif Groop; Barbara Thorand; Colin N Palmer; Anders Hamsten; Ulf de Faire; Everson Nogoceke; Shona J Livingstone; Veikko Salomaa; Karin Leander; Nicola Barbarini; Riccardo Bellazzi; Natalie van Zuydam; Paul M McKeigue; Helen M Colhoun
Journal:  Diabetologia       Date:  2015-03-05       Impact factor: 10.122

4.  Apolipoprotein A-II-mediated conformational changes of apolipoprotein A-I in discoidal high density lipoproteins.

Authors:  Kekulawalage Gauthamadasa; Nataraja Sarma Vaitinadin; James L Dressman; Stephen Macha; Reyn Homan; Kenneth D Greis; R A Gangani D Silva
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

5.  The Association between Apolipoprotein A-II and Metabolic Syndrome in Korean Adults: A Comparison Study of Apolipoprotein A-I and Apolipoprotein B.

Authors:  Dong Won Yi; Dong Wook Jeong; Sang Yeoup Lee; Seok Man Son; Yang Ho Kang
Journal:  Diabetes Metab J       Date:  2012-02-17       Impact factor: 5.376

6.  A pro-atherogenic HDL profile in coronary heart disease patients: an iTRAQ labelling-based proteomic approach.

Authors:  Li-rong Yan; Dong-xue Wang; Hong Liu; Xiao-xing Zhang; Hui Zhao; Lu Hua; Ping Xu; Yi-shi Li
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

7.  APO A2 -265T/C Polymorphism Is Associated with Increased Inflammatory Responses in Patients with Type 2 Diabetes Mellitus.

Authors:  Fariba Koohdani; Haleh Sadrzadeh-Yeganeh; Mahmoud Djalali; Mohammadreza Eshraghian; Elham Zamani; Gity Sotoudeh; Mohammad Ali Mansournia; Laleh Keramat
Journal:  Diabetes Metab J       Date:  2016-06       Impact factor: 5.376

8.  Association between lipoprotein cholesterol and future cardiovascular disease and mortality in older adults: a Korean nationwide longitudinal study.

Authors:  Seung Hee Kim; Ki Young Son
Journal:  Lipids Health Dis       Date:  2021-01-06       Impact factor: 3.876

9.  Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.

Authors:  Theodore W K Ng; Dick C Chan; P Hugh R Barrett; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2009-10-02       Impact factor: 6.124

Review 10.  Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis.

Authors:  Yurong Zhang; Gang Hu; Zuyi Yuan; Liwei Chen
Journal:  PLoS One       Date:  2012-08-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.